BPC-157 / TB-500 Blend
Repair combination
Research overview
A combined formulation of the two most-requested recovery peptides for research protocols.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $185 CAD
- Purity
- ≥99% (HPLC)
- Presentation
- 2×10 mg lyophilized vial
Order / inquire about BPC-157 / TB-500 Blend
Email our research desk for availability, batch Certificates of Analysis, and account setup. We respond to verified research inquiries from Canada only.
Verified Canadian research inquiries only · 18+
For laboratory research use only — not for human or veterinary use
BPC-157 / TB-500 Blend is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 18+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
Combination reference preparation of two separately studied repair peptides with complementary mechanisms: BPC-157 (cytoprotection and nitric-oxide-mediated angiogenesis) and TB-500 (actin sequestration and cell migration). Informally called the 'Wolverine' blend; it is an empirical combination, not a clinically validated single entity.
Mechanism of action
Convergent but distinct pathways: vascularization and cytoprotection (BPC-157 via VEGFR2/eNOS/Akt-PI3K) plus cell motility and re-epithelialization (TB-500 via G-actin sequestration through the LKKTET motif). The hypothesis is accelerated repair through parallel pathways; synergy is a mechanistic conjecture, not a demonstrated clinical finding.
Research areas
- Combined musculoskeletal repair
- Wound healing with improved vascularization
- Multifactorial tissue recovery
Studied effects in research models
- Complementary effects (angiogenesis + cell migration)
- Note: the synergy of the blend has not been validated in controlled trials
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Biomarkers tracked in related research
Discovery & background
A market-driven combination rather than a discovered molecule. The rationale is mechanistic complementarity: BPC-157 conditions the repair environment (angiogenesis, growth factors, NO pathway) while TB-500/Tβ4 supports cell migration via actin dynamics. No controlled trial has tested the specific combination against monotherapy arms.
Considerations & limitations
Research use only. No interaction or safety data exist for the combination in humans; neither component is approved by Health Canada or the FDA, and both are prohibited by WADA in sport. Precautions of both components accumulate — dual pro-angiogenic action makes it inappropriate with active malignancy/oncologic risk; avoid in pregnancy/lactation (no data); caution with anticoagulants and immunomodulators (theoretical additive risk). Require a COA confirming identity, HPLC purity of each peptide separately, declared ratio, and sterility/endotoxin testing. Evidence is limited to extrapolation from single-agent preclinical work.
References
- [1]Sikiric et al., 2020 (BPC-157 review) — Curr Neuropharmacol; PMID: 32175841
- [2]Goldstein, Hannappel & Kleinman, 2005 (thymosin β4) — Ann N Y Acad Sci; PMID: 17244705
- [3]Seiwerth et al., 2018 (BPC 157 angiogenesis) — Curr Pharm Des; PMID: 29769016